Fecal transplants and precision radiation may reboot liver cancer treatment
NCT ID NCT07463248
First seen Mar 13, 2026 · Last updated May 02, 2026 · Updated 8 times
Summary
This study tests whether adding fecal microbiota transplantation (FMT) and personalized radiation (PULSAR) to standard therapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be randomly assigned to either the new combo or a switch to second-line therapy. The goal is to see if the combo improves how long the cancer stays controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.